Plain-English translation of NCT05476939 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a new medication called works better than an existing medication called for treating diffuse intrinsic pontine glioma (DIPG) and related brainstem tumors. DIPG is a serious brain tumor that grows in the pons, a part of the brainstem. The study will randomly assign patients to receive one of these two medications and track how well each one works.
DIPG is a very aggressive tumor with limited treatment options, and current standard treatments don't work well enough for most patients. Researchers are testing this new medication to see if it can help patients live longer and have better outcomes.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to take either or as a daily tablet. You will visit the hospital regularly for check-ups, imaging scans to monitor your tumor, and blood tests. If your tumor grows despite treatment, you may have the option to switch to the other medication after a short break. The medication continues until your tumor progresses, side effects become too difficult to manage, or you choose to stop.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
Denmark
France